UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy

Nature chemical biology, 2014-12, Vol.10 (12), p.1013-1019

2014

Volltextzugriff (PDF)

Discovery of (2S)‑8-[(3R)‑3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro‑2H‑pyrimido[1,2‑a]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors

Journal of medicinal chemistry, 2015-01, Vol.58 (1), p.376-400

2015

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

Clinical and translational science, 2024-08, Vol.17 (8), p.e13874-n/a

2024

Volltextzugriff (PDF)

Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular Chaperone

Journal of medicinal chemistry, 2011-10, Vol.54 (20), p.7206-7219

2011

Volltextzugriff (PDF)

MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma

PloS one, 2014-01, Vol.9 (1), p.e84319

2014

Volltextzugriff (PDF)

The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer

Molecular cancer therapeutics, 2015-02, Vol.14 (2), p.384-394

2015

Volltextzugriff (PDF)

Discovery of (2 S )-8-[(3 R )-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2 H -pyrimido[1,2- a ]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors

Journal of medicinal chemistry, 2015-01, Vol.58 (1), p.376-400

2015

Volltextzugriff (PDF)

Abstract 3550: Inhibition of either LIN28A or ZCCHC11 (TUT4) provides distinct effects on the expression of the let-7 miRNA family and tumor cell proliferation

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3550-3550

2014

Volltextzugriff (PDF)

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

The New England journal of medicine, 2021-10, Vol.385 (18), p.1656-1668

2021

Volltextzugriff (PDF)

Abstract 563: A prospective biomarker study to demonstrate high MET expression and gene amplification in a subset of patients with advanced gastric cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.563-563

2014

Volltextzugriff (PDF)

The Bloom's Syndrome Gene Product Interacts with Topoisomerase III

The Journal of biological chemistry, 2000-03, Vol.275 (13), p.9636-9644

2000

Volltextzugriff (PDF)

Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

The lancet respiratory medicine, 2021-11, Vol.9 (11), p.1288-1298

2021

Volltextzugriff (PDF)

Abstract 845: In vitro and in vivo pharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.845-845

2012

Volltextzugriff (PDF)

Abstract 2911: SAR125844: a potent and selective ATP-competitive inhibitor of MET kinase

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2911-2911

2012

Volltextzugriff (PDF)

IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels

American journal of respiratory and critical care medicine, 2023-11, Vol.208 (10), p.1075-1087

2023

Volltextzugriff (PDF)

Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device and Prefilled Syringe in Healthy Participants

Clinical pharmacology in drug development, 2024-09

2024

Volltextzugriff (PDF)

IL-33 Expression Is Lower in Current Smokers at Both Transcriptomic and Protein Level

American journal of respiratory and critical care medicine, 2023-09

2023

Volltextzugriff (PDF)

Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein

Journal of Virology, 1996-01, Vol.70 (1), p.37-46

1996

Volltextzugriff (PDF)

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD

ERJ open research, 2024-09, Vol.10 (5), p.718

2024

Volltextzugriff (PDF)

Triple Helix Formation with Short Oligonucleotide-Intercalator Conjugates Matching the HIV-1 U3 LTR End Sequence

Biochemistry (Easton), 1994-04, Vol.33 (14), p.4187-4196

1994

Volltextzugriff (PDF)

Triplex-mediated inhibition of HIV DNA integration in vitro

The Journal of biological chemistry, 1994-08, Vol.269 (34), p.21635-21638

1994

Volltextzugriff (PDF)

Impairment of Moloney murine leukemia virus integration in a cell line underexpressing DNA topoisomerase II

Cancer research (Chicago, Ill.), 1995-07, Vol.55 (14), p.3211-3217

1995

Volltextzugriff (PDF)

Poly(pyrrolecarboxamides) linked to photoactivable chromophore isoalloxazine. Synthesis, selective binding, and DNA cleaving properties

Bioconjugate chemistry, 1994-01, Vol.5 (1), p.67-76

1994

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy

Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1‑{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3‑b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)

Discovery of (2S)‑8-[(3R)‑3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro‑2H‑pyrimido[1,2‑a]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular Chaperone

MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma

Correction to Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular Chaperone

The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer

Discovery of (2 S )-8-[(3 R )-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2 H -pyrimido[1,2- a ]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors

Abstract 3550: Inhibition of either LIN28A or ZCCHC11 (TUT4) provides distinct effects on the expression of the let-7 miRNA family and tumor cell proliferation

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

Abstract 563: A prospective biomarker study to demonstrate high MET expression and gene amplification in a subset of patients with advanced gastric cancer

The Bloom's Syndrome Gene Product Interacts with Topoisomerase III

Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

Abstract 845: In vitro and in vivo pharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial

Abstract 2911: SAR125844: a potent and selective ATP-competitive inhibitor of MET kinase

IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels

Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device and Prefilled Syringe in Healthy Participants

IL-33 Expression Is Lower in Current Smokers at Both Transcriptomic and Protein Level

Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD

Triple Helix Formation with Short Oligonucleotide-Intercalator Conjugates Matching the HIV-1 U3 LTR End Sequence

Triplex-mediated inhibition of HIV DNA integration in vitro

Impairment of Moloney murine leukemia virus integration in a cell line underexpressing DNA topoisomerase II

Poly(pyrrolecarboxamides) linked to photoactivable chromophore isoalloxazine. Synthesis, selective binding, and DNA cleaving properties

Suchergebnisse filtern